Cohen & SteersNYSE: CNS

HOUSTON, TX / ACCESSWIRE / June 26, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $2.45 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $2.32 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.

NEW YORK , June 24, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for July, August, and September 2024, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund $0.134 RFI Cohen & Steers Total Return Realty Fund, Inc. $0.080 RLTY Cohen & Steers Real Estate Opportunities and Income Fund $0.110 RNP Cohen & Steers REIT and Preferred and Income Fund, Inc. $0.136 RQI Cohen & Steers Quality Income Realty Fund, Inc. $0.080 UTF Cohen & Steers Infrastructure Fund, Inc. $0.155 Distributions will be made on the following schedule: Month Ex-Dividend/ Record Date Payable Date July Jul. 16, 2024 Jul. 31, 2024 August Aug. 13, 2024 Aug. 30, 2024 September Sept. 10, 2024 Sept.

Raja Dakkuri joins Cohen & Steers to succeed Matthew Stadler NEW YORK , June 24, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri has joined Cohen & Steers as Executive Vice President and Chief Financial Officer. Mr. Dakkuri succeeds Matthew Stadler, who previously notified Cohen & Steers on October 17, 2023 of his intention to retire during 2024 upon the appointment of his successor.

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL.

- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20 th at 8:00 am EDT - WARREN, N.J. , June 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients.

HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 366,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $3.75 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $3.62 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.

MARLBOROUGH, Mass. , June 13, 2024 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, announced the renewal and expansion of their agreement with A2 Hosting.

Cohen & Steers (CNS) reports an improvement in the May 2024 AUM balance on solid market performance.

ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch. ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis, which could create additional revenue verticals.